Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lucid Diagnostics (LUCD) Research & Development (2021 - 2025)

Lucid Diagnostics (LUCD) has disclosed Research & Development for 5 consecutive years, with $1.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Research & Development fell 23.65% year-over-year to $1.3 million, compared with a TTM value of $5.4 million through Sep 2025, down 16.25%, and an annual FY2024 reading of $6.0 million, down 17.37% over the prior year.
  • Research & Development was $1.3 million for Q3 2025 at Lucid Diagnostics, up from $1.3 million in the prior quarter.
  • Across five years, Research & Development topped out at $5.1 million in Q4 2021 and bottomed at $226200.0 in Q2 2021.
  • Average Research & Development over 5 years is $2.0 million, with a median of $1.8 million recorded in 2021.
  • Peak annual rise in Research & Development hit 1420.78% in 2022, while the deepest fall reached 56.47% in 2022.
  • Year by year, Research & Development stood at $5.1 million in 2021, then plummeted by 56.47% to $2.2 million in 2022, then dropped by 14.07% to $1.9 million in 2023, then dropped by 24.24% to $1.5 million in 2024, then fell by 12.46% to $1.3 million in 2025.
  • Business Quant data shows Research & Development for LUCD at $1.3 million in Q3 2025, $1.3 million in Q2 2025, and $1.4 million in Q1 2025.